nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—MTOR—hematologic cancer	0.235	0.74	CbGaD
Tacrolimus—ALB—hematologic cancer	0.0423	0.133	CbGaD
Tacrolimus—ABCB1—hematologic cancer	0.0404	0.127	CbGaD
Tacrolimus—ORM1—Imatinib—hematologic cancer	0.022	0.0654	CbGbCtD
Tacrolimus—ABCB1—Lenalidomide—hematologic cancer	0.0108	0.0321	CbGbCtD
Tacrolimus—CYP3A7—Ifosfamide—hematologic cancer	0.0104	0.0309	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.0104	0.0309	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.0099	0.0295	CbGbCtD
Tacrolimus—CYP3A7—Imatinib—hematologic cancer	0.0099	0.0295	CbGbCtD
Tacrolimus—CYP3A5—Daunorubicin—hematologic cancer	0.00969	0.0289	CbGbCtD
Tacrolimus—ALB—Imatinib—hematologic cancer	0.00924	0.0275	CbGbCtD
Tacrolimus—CYP3A5—Thalidomide—hematologic cancer	0.00883	0.0263	CbGbCtD
Tacrolimus—CYP3A5—Teniposide—hematologic cancer	0.00842	0.0251	CbGbCtD
Tacrolimus—CYP3A5—Ifosfamide—hematologic cancer	0.00777	0.0232	CbGbCtD
Tacrolimus—CYP3A5—Imatinib—hematologic cancer	0.00742	0.0221	CbGbCtD
Tacrolimus—CYP3A4—Bexarotene—hematologic cancer	0.00645	0.0192	CbGbCtD
Tacrolimus—ABCB1—Daunorubicin—hematologic cancer	0.00631	0.0188	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00618	0.0184	CbGbCtD
Tacrolimus—CYP3A7—Irinotecan—hematologic cancer	0.00618	0.0184	CbGbCtD
Tacrolimus—ABCB1—Alitretinoin—hematologic cancer	0.00618	0.0184	CbGbCtD
Tacrolimus—ALB—Prednisone—hematologic cancer	0.00609	0.0181	CbGbCtD
Tacrolimus—CYP3A4—Lomustine—hematologic cancer	0.00599	0.0179	CbGbCtD
Tacrolimus—CYP3A4—Busulfan—hematologic cancer	0.00599	0.0179	CbGbCtD
Tacrolimus—CYP3A5—Dasatinib—hematologic cancer	0.00596	0.0178	CbGbCtD
Tacrolimus—ALB—Irinotecan—hematologic cancer	0.00577	0.0172	CbGbCtD
Tacrolimus—CYP3A7—Vincristine—hematologic cancer	0.0054	0.0161	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.0054	0.0161	CbGbCtD
Tacrolimus—CYP3A4—Thiotepa—hematologic cancer	0.00534	0.0159	CbGbCtD
Tacrolimus—ABCB1—Imatinib—hematologic cancer	0.00483	0.0144	CbGbCtD
Tacrolimus—CYP3A5—Irinotecan—hematologic cancer	0.00464	0.0138	CbGbCtD
Tacrolimus—ABCB1—Nilotinib—hematologic cancer	0.00439	0.0131	CbGbCtD
Tacrolimus—ABCB1—Vinorelbine—hematologic cancer	0.00435	0.013	CbGbCtD
Tacrolimus—CYP3A4—Methoxsalen—hematologic cancer	0.00415	0.0124	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00407	0.0121	CbGbCtD
Tacrolimus—CYP3A7—Dexamethasone—hematologic cancer	0.00407	0.0121	CbGbCtD
Tacrolimus—CYP3A5—Vincristine—hematologic cancer	0.00405	0.0121	CbGbCtD
Tacrolimus—CYP3A4—Bortezomib—hematologic cancer	0.00395	0.0118	CbGbCtD
Tacrolimus—ABCB1—Dasatinib—hematologic cancer	0.00388	0.0116	CbGbCtD
Tacrolimus—ABCB1—Mitoxantrone—hematologic cancer	0.00383	0.0114	CbGbCtD
Tacrolimus—CYP3A4—Daunorubicin—hematologic cancer	0.00378	0.0113	CbGbCtD
Tacrolimus—CYP3A5—Etoposide—hematologic cancer	0.00371	0.0111	CbGbCtD
Tacrolimus—ABCB1—Betamethasone—hematologic cancer	0.00342	0.0102	CbGbCtD
Tacrolimus—ABCB1—Gemcitabine—hematologic cancer	0.00339	0.0101	CbGbCtD
Tacrolimus—ABCB1—Prednisolone—hematologic cancer	0.00337	0.01	CbGbCtD
Tacrolimus—CYP3A4—Cytarabine—hematologic cancer	0.00333	0.00993	CbGbCtD
Tacrolimus—CYP3A4—Teniposide—hematologic cancer	0.00328	0.00978	CbGbCtD
Tacrolimus—ABCB1—Prednisone—hematologic cancer	0.00318	0.00948	CbGbCtD
Tacrolimus—CYP3A5—Dexamethasone—hematologic cancer	0.00305	0.0091	CbGbCtD
Tacrolimus—ALB—Methotrexate—hematologic cancer	0.00305	0.0091	CbGbCtD
Tacrolimus—CYP3A4—Ifosfamide—hematologic cancer	0.00303	0.00903	CbGbCtD
Tacrolimus—ABCB1—Irinotecan—hematologic cancer	0.00302	0.00899	CbGbCtD
Tacrolimus—CYP3A4—Imatinib—hematologic cancer	0.0029	0.00862	CbGbCtD
Tacrolimus—CYP3A4—Ruxolitinib—hematologic cancer	0.00273	0.00812	CbGbCtD
Tacrolimus—ABCB1—Vinblastine—hematologic cancer	0.00268	0.00799	CbGbCtD
Tacrolimus—ABCB1—Vincristine—hematologic cancer	0.00264	0.00786	CbGbCtD
Tacrolimus—CYP3A4—Nilotinib—hematologic cancer	0.00263	0.00784	CbGbCtD
Tacrolimus—CYP3A4—Vinorelbine—hematologic cancer	0.00261	0.00777	CbGbCtD
Tacrolimus—ABCB1—Cisplatin—hematologic cancer	0.00246	0.00733	CbGbCtD
Tacrolimus—ABCB1—Etoposide—hematologic cancer	0.00242	0.0072	CbGbCtD
Tacrolimus—CYP3A4—Triamcinolone—hematologic cancer	0.00239	0.00711	CbGbCtD
Tacrolimus—CYP3A4—Dasatinib—hematologic cancer	0.00233	0.00693	CbGbCtD
Tacrolimus—CYP3A4—Mitoxantrone—hematologic cancer	0.0023	0.00684	CbGbCtD
Tacrolimus—CYP3A4—Betamethasone—hematologic cancer	0.00205	0.0061	CbGbCtD
Tacrolimus—CYP3A4—Prednisolone—hematologic cancer	0.00202	0.00602	CbGbCtD
Tacrolimus—ABCA5—gonad—hematologic cancer	0.002	0.0579	CbGeAlD
Tacrolimus—ABCB1—Dexamethasone—hematologic cancer	0.00199	0.00592	CbGbCtD
Tacrolimus—CYP3A4—Prednisone—hematologic cancer	0.00191	0.00568	CbGbCtD
Tacrolimus—CYP3A4—Irinotecan—hematologic cancer	0.00181	0.00539	CbGbCtD
Tacrolimus—PPP3CA—hematopoietic system—hematologic cancer	0.00177	0.0514	CbGeAlD
Tacrolimus—ABCA5—blood—hematologic cancer	0.00174	0.0505	CbGeAlD
Tacrolimus—ABCA5—bone marrow—hematologic cancer	0.00168	0.0488	CbGeAlD
Tacrolimus—ABCB1—Doxorubicin—hematologic cancer	0.00165	0.00491	CbGbCtD
Tacrolimus—CYP3A4—Vinblastine—hematologic cancer	0.00161	0.00479	CbGbCtD
Tacrolimus—ABCB1—Methotrexate—hematologic cancer	0.0016	0.00476	CbGbCtD
Tacrolimus—CYP3A4—Vincristine—hematologic cancer	0.00158	0.00471	CbGbCtD
Tacrolimus—ABCA5—lung—hematologic cancer	0.00153	0.0442	CbGeAlD
Tacrolimus—CYP3A4—Etoposide—hematologic cancer	0.00145	0.00431	CbGbCtD
Tacrolimus—ABCA5—testis—hematologic cancer	0.00144	0.0417	CbGeAlD
Tacrolimus—MTOR—hematopoietic system—hematologic cancer	0.00131	0.038	CbGeAlD
Tacrolimus—CYP3A4—Dexamethasone—hematologic cancer	0.00119	0.00355	CbGbCtD
Tacrolimus—FKBP1A—hematopoietic system—hematologic cancer	0.00118	0.0342	CbGeAlD
Tacrolimus—PPP3CA—blood—hematologic cancer	0.00118	0.0341	CbGeAlD
Tacrolimus—PPP3CA—bone marrow—hematologic cancer	0.00114	0.033	CbGeAlD
Tacrolimus—ABCA5—lymph node—hematologic cancer	0.00104	0.0303	CbGeAlD
Tacrolimus—PPP3CA—lung—hematologic cancer	0.00103	0.0299	CbGeAlD
Tacrolimus—MTOR—gonad—hematologic cancer	0.000997	0.0289	CbGeAlD
Tacrolimus—CYP3A4—Doxorubicin—hematologic cancer	0.000988	0.00294	CbGbCtD
Tacrolimus—PPP3CA—testis—hematologic cancer	0.000973	0.0282	CbGeAlD
Tacrolimus—ORM1—hematopoietic system—hematologic cancer	0.000923	0.0268	CbGeAlD
Tacrolimus—FKBP1A—gonad—hematologic cancer	0.000897	0.026	CbGeAlD
Tacrolimus—MTOR—blood—hematologic cancer	0.000869	0.0252	CbGeAlD
Tacrolimus—Everolimus—MTOR—hematologic cancer	0.00086	0.237	CrCbGaD
Tacrolimus—Pimecrolimus—MTOR—hematologic cancer	0.00086	0.237	CrCbGaD
Tacrolimus—MTOR—bone marrow—hematologic cancer	0.00084	0.0244	CbGeAlD
Tacrolimus—FKBP1A—blood—hematologic cancer	0.000781	0.0226	CbGeAlD
Tacrolimus—MTOR—lung—hematologic cancer	0.000761	0.0221	CbGeAlD
Tacrolimus—FKBP1A—bone marrow—hematologic cancer	0.000756	0.0219	CbGeAlD
Tacrolimus—MTOR—testis—hematologic cancer	0.000718	0.0208	CbGeAlD
Tacrolimus—PPP3CA—lymph node—hematologic cancer	0.000705	0.0204	CbGeAlD
Tacrolimus—FKBP1A—lung—hematologic cancer	0.000685	0.0199	CbGeAlD
Tacrolimus—FKBP1A—testis—hematologic cancer	0.000646	0.0187	CbGeAlD
Tacrolimus—Sirolimus—FGF2—hematologic cancer	0.000627	0.173	CrCbGaD
Tacrolimus—ORM1—blood—hematologic cancer	0.000612	0.0177	CbGeAlD
Tacrolimus—ORM1—bone marrow—hematologic cancer	0.000592	0.0172	CbGeAlD
Tacrolimus—Temsirolimus—MTOR—hematologic cancer	0.000581	0.16	CrCbGaD
Tacrolimus—ORM1—lung—hematologic cancer	0.000536	0.0155	CbGeAlD
Tacrolimus—MTOR—lymph node—hematologic cancer	0.000521	0.0151	CbGeAlD
Tacrolimus—CYP3A5—hematopoietic system—hematologic cancer	0.000513	0.0149	CbGeAlD
Tacrolimus—Sirolimus—MTOR—hematologic cancer	0.000511	0.141	CrCbGaD
Tacrolimus—FKBP1A—lymph node—hematologic cancer	0.000468	0.0136	CbGeAlD
Tacrolimus—ALB—testis—hematologic cancer	0.000444	0.0129	CbGeAlD
Tacrolimus—CYP3A4—hematopoietic system—hematologic cancer	0.000385	0.0112	CbGeAlD
Tacrolimus—ORM1—lymph node—hematologic cancer	0.000367	0.0106	CbGeAlD
Tacrolimus—CYP3A5—blood—hematologic cancer	0.00034	0.00986	CbGeAlD
Tacrolimus—ALB—lymph node—hematologic cancer	0.000322	0.00932	CbGeAlD
Tacrolimus—CYP3A5—lung—hematologic cancer	0.000298	0.00865	CbGeAlD
Tacrolimus—ABCB1—hematopoietic system—hematologic cancer	0.000273	0.00791	CbGeAlD
Tacrolimus—CYP3A4—blood—hematologic cancer	0.000255	0.0074	CbGeAlD
Tacrolimus—ABCB1—gonad—hematologic cancer	0.000207	0.00601	CbGeAlD
Tacrolimus—ABCB1—blood—hematologic cancer	0.000181	0.00524	CbGeAlD
Tacrolimus—ABCB1—bone marrow—hematologic cancer	0.000175	0.00507	CbGeAlD
Tacrolimus—ABCB1—lung—hematologic cancer	0.000158	0.00459	CbGeAlD
Tacrolimus—ABCB1—testis—hematologic cancer	0.000149	0.00433	CbGeAlD
Tacrolimus—ABCB1—lymph node—hematologic cancer	0.000108	0.00314	CbGeAlD
Tacrolimus—Temsirolimus—ABCB1—hematologic cancer	9.98e-05	0.0275	CrCbGaD
Tacrolimus—Sirolimus—ABCB1—hematologic cancer	8.79e-05	0.0242	CrCbGaD
Tacrolimus—Flatulence—Epirubicin—hematologic cancer	5.74e-06	2.82e-05	CcSEcCtD
Tacrolimus—Tension—Epirubicin—hematologic cancer	5.72e-06	2.81e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.71e-06	2.8e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Betamethasone—hematologic cancer	5.71e-06	2.8e-05	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—hematologic cancer	5.71e-06	2.8e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Triamcinolone—hematologic cancer	5.67e-06	2.78e-05	CcSEcCtD
Tacrolimus—Nervousness—Epirubicin—hematologic cancer	5.66e-06	2.78e-05	CcSEcCtD
Tacrolimus—Back pain—Epirubicin—hematologic cancer	5.64e-06	2.77e-05	CcSEcCtD
Tacrolimus—Angiopathy—Doxorubicin—hematologic cancer	5.62e-06	2.76e-05	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—hematologic cancer	5.62e-06	2.76e-05	CcSEcCtD
Tacrolimus—Dizziness—Etoposide—hematologic cancer	5.61e-06	2.76e-05	CcSEcCtD
Tacrolimus—Muscle spasms—Epirubicin—hematologic cancer	5.6e-06	2.75e-05	CcSEcCtD
Tacrolimus—Immune system disorder—Doxorubicin—hematologic cancer	5.6e-06	2.75e-05	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—hematologic cancer	5.6e-06	2.75e-05	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—hematologic cancer	5.58e-06	2.74e-05	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—hematologic cancer	5.58e-06	2.74e-05	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—hematologic cancer	5.56e-06	2.73e-05	CcSEcCtD
Tacrolimus—Urticaria—Betamethasone—hematologic cancer	5.55e-06	2.72e-05	CcSEcCtD
Tacrolimus—Urticaria—Dexamethasone—hematologic cancer	5.55e-06	2.72e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.54e-06	2.72e-05	CcSEcCtD
Tacrolimus—Dizziness—Prednisolone—hematologic cancer	5.54e-06	2.72e-05	CcSEcCtD
Tacrolimus—Arrhythmia—Doxorubicin—hematologic cancer	5.53e-06	2.72e-05	CcSEcCtD
Tacrolimus—Asthenia—Triamcinolone—hematologic cancer	5.52e-06	2.71e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Betamethasone—hematologic cancer	5.52e-06	2.71e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Dexamethasone—hematologic cancer	5.52e-06	2.71e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Dexamethasone—hematologic cancer	5.52e-06	2.71e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Betamethasone—hematologic cancer	5.52e-06	2.71e-05	CcSEcCtD
Tacrolimus—Nausea—Cisplatin—hematologic cancer	5.5e-06	2.7e-05	CcSEcCtD
Tacrolimus—Insomnia—Prednisone—hematologic cancer	5.5e-06	2.7e-05	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—hematologic cancer	5.49e-06	2.7e-05	CcSEcCtD
Tacrolimus—Alopecia—Doxorubicin—hematologic cancer	5.47e-06	2.69e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Prednisone—hematologic cancer	5.46e-06	2.68e-05	CcSEcCtD
Tacrolimus—Pruritus—Triamcinolone—hematologic cancer	5.45e-06	2.67e-05	CcSEcCtD
Tacrolimus—Cough—Methotrexate—hematologic cancer	5.44e-06	2.67e-05	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—hematologic cancer	5.43e-06	2.67e-05	CcSEcCtD
Tacrolimus—Ill-defined disorder—Epirubicin—hematologic cancer	5.41e-06	2.66e-05	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—hematologic cancer	5.4e-06	2.65e-05	CcSEcCtD
Tacrolimus—Vomiting—Etoposide—hematologic cancer	5.4e-06	2.65e-05	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—hematologic cancer	5.39e-06	2.65e-05	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—hematologic cancer	5.39e-06	2.65e-05	CcSEcCtD
Tacrolimus—Anaemia—Epirubicin—hematologic cancer	5.39e-06	2.65e-05	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—hematologic cancer	5.36e-06	2.63e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Prednisone—hematologic cancer	5.35e-06	2.63e-05	CcSEcCtD
Tacrolimus—Rash—Etoposide—hematologic cancer	5.35e-06	2.63e-05	CcSEcCtD
Tacrolimus—Dermatitis—Etoposide—hematologic cancer	5.35e-06	2.63e-05	CcSEcCtD
Tacrolimus—Headache—Etoposide—hematologic cancer	5.32e-06	2.61e-05	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—hematologic cancer	5.31e-06	2.61e-05	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—hematologic cancer	5.3e-06	2.6e-05	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—hematologic cancer	5.3e-06	2.6e-05	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—hematologic cancer	5.3e-06	2.6e-05	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—hematologic cancer	5.29e-06	2.6e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Prednisone—hematologic cancer	5.29e-06	2.6e-05	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—hematologic cancer	5.28e-06	2.59e-05	CcSEcCtD
Tacrolimus—Rash—Prednisolone—hematologic cancer	5.28e-06	2.59e-05	CcSEcCtD
Tacrolimus—Dermatitis—Prednisolone—hematologic cancer	5.27e-06	2.59e-05	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.27e-06	2.59e-05	CcSEcCtD
Tacrolimus—Malaise—Epirubicin—hematologic cancer	5.26e-06	2.58e-05	CcSEcCtD
Tacrolimus—Fatigue—Prednisone—hematologic cancer	5.24e-06	2.58e-05	CcSEcCtD
Tacrolimus—Headache—Prednisolone—hematologic cancer	5.24e-06	2.57e-05	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—hematologic cancer	5.24e-06	2.57e-05	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—hematologic cancer	5.24e-06	2.57e-05	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—hematologic cancer	5.24e-06	2.57e-05	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—hematologic cancer	5.23e-06	2.57e-05	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—hematologic cancer	5.22e-06	2.56e-05	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—hematologic cancer	5.22e-06	2.56e-05	CcSEcCtD
Tacrolimus—Constipation—Prednisone—hematologic cancer	5.2e-06	2.55e-05	CcSEcCtD
Tacrolimus—Muscle spasms—Doxorubicin—hematologic cancer	5.19e-06	2.55e-05	CcSEcCtD
Tacrolimus—Palpitations—Epirubicin—hematologic cancer	5.15e-06	2.53e-05	CcSEcCtD
Tacrolimus—Confusional state—Methotrexate—hematologic cancer	5.13e-06	2.52e-05	CcSEcCtD
Tacrolimus—Loss of consciousness—Epirubicin—hematologic cancer	5.12e-06	2.52e-05	CcSEcCtD
Tacrolimus—Dizziness—Triamcinolone—hematologic cancer	5.09e-06	2.5e-05	CcSEcCtD
Tacrolimus—Cough—Epirubicin—hematologic cancer	5.09e-06	2.5e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Methotrexate—hematologic cancer	5.08e-06	2.5e-05	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—hematologic cancer	5.08e-06	2.5e-05	CcSEcCtD
Tacrolimus—Convulsion—Epirubicin—hematologic cancer	5.05e-06	2.48e-05	CcSEcCtD
Tacrolimus—Infection—Methotrexate—hematologic cancer	5.05e-06	2.48e-05	CcSEcCtD
Tacrolimus—Nausea—Etoposide—hematologic cancer	5.04e-06	2.48e-05	CcSEcCtD
Tacrolimus—Hypertension—Epirubicin—hematologic cancer	5.03e-06	2.47e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Prednisone—hematologic cancer	5.01e-06	2.46e-05	CcSEcCtD
Tacrolimus—Asthenia—Betamethasone—hematologic cancer	5.01e-06	2.46e-05	CcSEcCtD
Tacrolimus—Asthenia—Dexamethasone—hematologic cancer	5.01e-06	2.46e-05	CcSEcCtD
Tacrolimus—Ill-defined disorder—Doxorubicin—hematologic cancer	5e-06	2.46e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—hematologic cancer	4.99e-06	2.45e-05	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—hematologic cancer	4.98e-06	2.45e-05	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—hematologic cancer	4.98e-06	2.44e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Prednisone—hematologic cancer	4.97e-06	2.44e-05	CcSEcCtD
Tacrolimus—Nausea—Prednisolone—hematologic cancer	4.97e-06	2.44e-05	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—hematologic cancer	4.96e-06	2.44e-05	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—hematologic cancer	4.96e-06	2.44e-05	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—hematologic cancer	4.96e-06	2.44e-05	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—hematologic cancer	4.96e-06	2.43e-05	CcSEcCtD
Tacrolimus—Anxiety—Epirubicin—hematologic cancer	4.95e-06	2.43e-05	CcSEcCtD
Tacrolimus—Pruritus—Dexamethasone—hematologic cancer	4.94e-06	2.43e-05	CcSEcCtD
Tacrolimus—Pruritus—Betamethasone—hematologic cancer	4.94e-06	2.43e-05	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—hematologic cancer	4.94e-06	2.42e-05	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.93e-06	2.42e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—hematologic cancer	4.91e-06	2.41e-05	CcSEcCtD
Tacrolimus—Discomfort—Epirubicin—hematologic cancer	4.9e-06	2.41e-05	CcSEcCtD
Tacrolimus—Vomiting—Triamcinolone—hematologic cancer	4.89e-06	2.4e-05	CcSEcCtD
Tacrolimus—Malaise—Doxorubicin—hematologic cancer	4.86e-06	2.39e-05	CcSEcCtD
Tacrolimus—Rash—Triamcinolone—hematologic cancer	4.85e-06	2.38e-05	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—hematologic cancer	4.85e-06	2.38e-05	CcSEcCtD
Tacrolimus—Dermatitis—Triamcinolone—hematologic cancer	4.85e-06	2.38e-05	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—hematologic cancer	4.85e-06	2.38e-05	CcSEcCtD
Tacrolimus—Anorexia—Methotrexate—hematologic cancer	4.85e-06	2.38e-05	CcSEcCtD
Tacrolimus—Syncope—Doxorubicin—hematologic cancer	4.84e-06	2.37e-05	CcSEcCtD
Tacrolimus—Urticaria—Prednisone—hematologic cancer	4.83e-06	2.37e-05	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—hematologic cancer	4.83e-06	2.37e-05	CcSEcCtD
Tacrolimus—Headache—Triamcinolone—hematologic cancer	4.82e-06	2.37e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Prednisone—hematologic cancer	4.81e-06	2.36e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Prednisone—hematologic cancer	4.81e-06	2.36e-05	CcSEcCtD
Tacrolimus—Confusional state—Epirubicin—hematologic cancer	4.8e-06	2.36e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Betamethasone—hematologic cancer	4.78e-06	2.35e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Dexamethasone—hematologic cancer	4.78e-06	2.35e-05	CcSEcCtD
Tacrolimus—Palpitations—Doxorubicin—hematologic cancer	4.77e-06	2.34e-05	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—hematologic cancer	4.76e-06	2.34e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—hematologic cancer	4.76e-06	2.34e-05	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—hematologic cancer	4.75e-06	2.33e-05	CcSEcCtD
Tacrolimus—Loss of consciousness—Doxorubicin—hematologic cancer	4.74e-06	2.33e-05	CcSEcCtD
Tacrolimus—Infection—Epirubicin—hematologic cancer	4.73e-06	2.32e-05	CcSEcCtD
Tacrolimus—Cough—Doxorubicin—hematologic cancer	4.71e-06	2.31e-05	CcSEcCtD
Tacrolimus—Shock—Epirubicin—hematologic cancer	4.68e-06	2.3e-05	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—hematologic cancer	4.67e-06	2.29e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—hematologic cancer	4.67e-06	2.29e-05	CcSEcCtD
Tacrolimus—Thrombocytopenia—Epirubicin—hematologic cancer	4.66e-06	2.29e-05	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—hematologic cancer	4.66e-06	2.29e-05	CcSEcCtD
Tacrolimus—Tachycardia—Epirubicin—hematologic cancer	4.64e-06	2.28e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.63e-06	2.27e-05	CcSEcCtD
Tacrolimus—Skin disorder—Epirubicin—hematologic cancer	4.62e-06	2.27e-05	CcSEcCtD
Tacrolimus—Dizziness—Betamethasone—hematologic cancer	4.62e-06	2.27e-05	CcSEcCtD
Tacrolimus—Dizziness—Dexamethasone—hematologic cancer	4.62e-06	2.27e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Epirubicin—hematologic cancer	4.6e-06	2.26e-05	CcSEcCtD
Tacrolimus—Insomnia—Methotrexate—hematologic cancer	4.6e-06	2.26e-05	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—hematologic cancer	4.59e-06	2.25e-05	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—hematologic cancer	4.59e-06	2.25e-05	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—hematologic cancer	4.59e-06	2.25e-05	CcSEcCtD
Tacrolimus—Anxiety—Doxorubicin—hematologic cancer	4.58e-06	2.25e-05	CcSEcCtD
Tacrolimus—Nausea—Triamcinolone—hematologic cancer	4.57e-06	2.25e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Methotrexate—hematologic cancer	4.56e-06	2.24e-05	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.56e-06	2.24e-05	CcSEcCtD
Tacrolimus—Discomfort—Doxorubicin—hematologic cancer	4.54e-06	2.23e-05	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—hematologic cancer	4.53e-06	2.23e-05	CcSEcCtD
Tacrolimus—Dyspnoea—Methotrexate—hematologic cancer	4.53e-06	2.23e-05	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—hematologic cancer	4.52e-06	2.22e-05	CcSEcCtD
Tacrolimus—Dry mouth—Doxorubicin—hematologic cancer	4.49e-06	2.21e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Prednisone—hematologic cancer	4.48e-06	2.2e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—hematologic cancer	4.47e-06	2.2e-05	CcSEcCtD
Tacrolimus—Hypotension—Epirubicin—hematologic cancer	4.45e-06	2.18e-05	CcSEcCtD
Tacrolimus—Vomiting—Dexamethasone—hematologic cancer	4.44e-06	2.18e-05	CcSEcCtD
Tacrolimus—Vomiting—Betamethasone—hematologic cancer	4.44e-06	2.18e-05	CcSEcCtD
Tacrolimus—Confusional state—Doxorubicin—hematologic cancer	4.44e-06	2.18e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Methotrexate—hematologic cancer	4.42e-06	2.17e-05	CcSEcCtD
Tacrolimus—Rash—Betamethasone—hematologic cancer	4.4e-06	2.16e-05	CcSEcCtD
Tacrolimus—Rash—Dexamethasone—hematologic cancer	4.4e-06	2.16e-05	CcSEcCtD
Tacrolimus—Oedema—Doxorubicin—hematologic cancer	4.4e-06	2.16e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—hematologic cancer	4.4e-06	2.16e-05	CcSEcCtD
Tacrolimus—Dermatitis—Betamethasone—hematologic cancer	4.4e-06	2.16e-05	CcSEcCtD
Tacrolimus—Dermatitis—Dexamethasone—hematologic cancer	4.4e-06	2.16e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.39e-06	2.15e-05	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—hematologic cancer	4.38e-06	2.15e-05	CcSEcCtD
Tacrolimus—Headache—Dexamethasone—hematologic cancer	4.38e-06	2.15e-05	CcSEcCtD
Tacrolimus—Headache—Betamethasone—hematologic cancer	4.38e-06	2.15e-05	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—hematologic cancer	4.37e-06	2.15e-05	CcSEcCtD
Tacrolimus—Asthenia—Prednisone—hematologic cancer	4.36e-06	2.14e-05	CcSEcCtD
Tacrolimus—Pain—Methotrexate—hematologic cancer	4.35e-06	2.13e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.33e-06	2.13e-05	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—hematologic cancer	4.33e-06	2.13e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—hematologic cancer	4.32e-06	2.12e-05	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—hematologic cancer	4.31e-06	2.12e-05	CcSEcCtD
Tacrolimus—Pruritus—Prednisone—hematologic cancer	4.3e-06	2.11e-05	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—hematologic cancer	4.3e-06	2.11e-05	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—hematologic cancer	4.3e-06	2.11e-05	CcSEcCtD
Tacrolimus—Skin disorder—Doxorubicin—hematologic cancer	4.28e-06	2.1e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—hematologic cancer	4.27e-06	2.1e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Doxorubicin—hematologic cancer	4.26e-06	2.09e-05	CcSEcCtD
Tacrolimus—Dyspnoea—Epirubicin—hematologic cancer	4.24e-06	2.08e-05	CcSEcCtD
Tacrolimus—Somnolence—Epirubicin—hematologic cancer	4.23e-06	2.08e-05	CcSEcCtD
Tacrolimus—Anorexia—Doxorubicin—hematologic cancer	4.2e-06	2.06e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Methotrexate—hematologic cancer	4.19e-06	2.06e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Epirubicin—hematologic cancer	4.19e-06	2.06e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Prednisone—hematologic cancer	4.16e-06	2.04e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—hematologic cancer	4.16e-06	2.04e-05	CcSEcCtD
Tacrolimus—Nausea—Betamethasone—hematologic cancer	4.15e-06	2.04e-05	CcSEcCtD
Tacrolimus—Nausea—Dexamethasone—hematologic cancer	4.15e-06	2.04e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Epirubicin—hematologic cancer	4.14e-06	2.03e-05	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—hematologic cancer	4.11e-06	2.02e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.11e-06	2.02e-05	CcSEcCtD
Tacrolimus—Fatigue—Epirubicin—hematologic cancer	4.1e-06	2.01e-05	CcSEcCtD
Tacrolimus—Constipation—Epirubicin—hematologic cancer	4.07e-06	2e-05	CcSEcCtD
Tacrolimus—Pain—Epirubicin—hematologic cancer	4.07e-06	2e-05	CcSEcCtD
Tacrolimus—Urticaria—Methotrexate—hematologic cancer	4.04e-06	1.98e-05	CcSEcCtD
Tacrolimus—Dizziness—Prednisone—hematologic cancer	4.02e-06	1.98e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—hematologic cancer	4.02e-06	1.97e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—hematologic cancer	4.02e-06	1.97e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.01e-06	1.97e-05	CcSEcCtD
Tacrolimus—Insomnia—Doxorubicin—hematologic cancer	3.98e-06	1.95e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Doxorubicin—hematologic cancer	3.95e-06	1.94e-05	CcSEcCtD
Tacrolimus—Dyspnoea—Doxorubicin—hematologic cancer	3.92e-06	1.93e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Epirubicin—hematologic cancer	3.92e-06	1.92e-05	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—hematologic cancer	3.91e-06	1.92e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Epirubicin—hematologic cancer	3.89e-06	1.91e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Doxorubicin—hematologic cancer	3.87e-06	1.9e-05	CcSEcCtD
Tacrolimus—Vomiting—Prednisone—hematologic cancer	3.87e-06	1.9e-05	CcSEcCtD
Tacrolimus—Rash—Prednisone—hematologic cancer	3.84e-06	1.88e-05	CcSEcCtD
Tacrolimus—Dermatitis—Prednisone—hematologic cancer	3.83e-06	1.88e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Doxorubicin—hematologic cancer	3.83e-06	1.88e-05	CcSEcCtD
Tacrolimus—Headache—Prednisone—hematologic cancer	3.81e-06	1.87e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.8e-06	1.87e-05	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—hematologic cancer	3.8e-06	1.86e-05	CcSEcCtD
Tacrolimus—Urticaria—Epirubicin—hematologic cancer	3.78e-06	1.86e-05	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—hematologic cancer	3.76e-06	1.85e-05	CcSEcCtD
Tacrolimus—Constipation—Doxorubicin—hematologic cancer	3.76e-06	1.85e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—hematologic cancer	3.76e-06	1.85e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—hematologic cancer	3.76e-06	1.85e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Methotrexate—hematologic cancer	3.75e-06	1.84e-05	CcSEcCtD
Tacrolimus—Asthenia—Methotrexate—hematologic cancer	3.65e-06	1.79e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Doxorubicin—hematologic cancer	3.63e-06	1.78e-05	CcSEcCtD
Tacrolimus—Nausea—Prednisone—hematologic cancer	3.61e-06	1.77e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.6e-06	1.77e-05	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—hematologic cancer	3.6e-06	1.77e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Epirubicin—hematologic cancer	3.5e-06	1.72e-05	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—hematologic cancer	3.5e-06	1.72e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Doxorubicin—hematologic cancer	3.48e-06	1.71e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Doxorubicin—hematologic cancer	3.48e-06	1.71e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Methotrexate—hematologic cancer	3.48e-06	1.71e-05	CcSEcCtD
Tacrolimus—Asthenia—Epirubicin—hematologic cancer	3.41e-06	1.68e-05	CcSEcCtD
Tacrolimus—Pruritus—Epirubicin—hematologic cancer	3.37e-06	1.65e-05	CcSEcCtD
Tacrolimus—Dizziness—Methotrexate—hematologic cancer	3.36e-06	1.65e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Epirubicin—hematologic cancer	3.25e-06	1.6e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Doxorubicin—hematologic cancer	3.24e-06	1.59e-05	CcSEcCtD
Tacrolimus—Vomiting—Methotrexate—hematologic cancer	3.23e-06	1.59e-05	CcSEcCtD
Tacrolimus—Rash—Methotrexate—hematologic cancer	3.21e-06	1.57e-05	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—hematologic cancer	3.2e-06	1.57e-05	CcSEcCtD
Tacrolimus—Headache—Methotrexate—hematologic cancer	3.18e-06	1.56e-05	CcSEcCtD
Tacrolimus—Asthenia—Doxorubicin—hematologic cancer	3.16e-06	1.55e-05	CcSEcCtD
Tacrolimus—Dizziness—Epirubicin—hematologic cancer	3.15e-06	1.54e-05	CcSEcCtD
Tacrolimus—Pruritus—Doxorubicin—hematologic cancer	3.11e-06	1.53e-05	CcSEcCtD
Tacrolimus—Vomiting—Epirubicin—hematologic cancer	3.02e-06	1.49e-05	CcSEcCtD
Tacrolimus—Nausea—Methotrexate—hematologic cancer	3.02e-06	1.48e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Doxorubicin—hematologic cancer	3.01e-06	1.48e-05	CcSEcCtD
Tacrolimus—Rash—Epirubicin—hematologic cancer	3e-06	1.47e-05	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—hematologic cancer	3e-06	1.47e-05	CcSEcCtD
Tacrolimus—Headache—Epirubicin—hematologic cancer	2.98e-06	1.46e-05	CcSEcCtD
Tacrolimus—Dizziness—Doxorubicin—hematologic cancer	2.91e-06	1.43e-05	CcSEcCtD
Tacrolimus—Nausea—Epirubicin—hematologic cancer	2.83e-06	1.39e-05	CcSEcCtD
Tacrolimus—Vomiting—Doxorubicin—hematologic cancer	2.8e-06	1.37e-05	CcSEcCtD
Tacrolimus—Rash—Doxorubicin—hematologic cancer	2.78e-06	1.36e-05	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—hematologic cancer	2.77e-06	1.36e-05	CcSEcCtD
Tacrolimus—Headache—Doxorubicin—hematologic cancer	2.76e-06	1.35e-05	CcSEcCtD
Tacrolimus—Nausea—Doxorubicin—hematologic cancer	2.61e-06	1.28e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—hematologic cancer	2.29e-06	2.19e-05	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.29e-06	2.18e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	2.28e-06	2.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PDGFB—hematologic cancer	2.28e-06	2.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—JAK2—hematologic cancer	2.26e-06	2.16e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAPK8—hematologic cancer	2.26e-06	2.16e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—hematologic cancer	2.25e-06	2.15e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ABCG2—hematologic cancer	2.25e-06	2.15e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MTR—hematologic cancer	2.25e-06	2.15e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYCS—hematologic cancer	2.23e-06	2.13e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TSC2—hematologic cancer	2.22e-06	2.12e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HSP90AA1—hematologic cancer	2.21e-06	2.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MDM2—hematologic cancer	2.21e-06	2.11e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—MTHFR—hematologic cancer	2.21e-06	2.11e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EP300—hematologic cancer	2.21e-06	2.11e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ENO2—hematologic cancer	2.2e-06	2.1e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1B—hematologic cancer	2.19e-06	2.09e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CB—hematologic cancer	2.18e-06	2.08e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—hematologic cancer	2.17e-06	2.07e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IL6—hematologic cancer	2.16e-06	2.06e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—hematologic cancer	2.16e-06	2.06e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.15e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CB—hematologic cancer	2.15e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—FHL2—hematologic cancer	2.15e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL1B—hematologic cancer	2.15e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD4—hematologic cancer	2.15e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SRC—hematologic cancer	2.14e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGFR3—hematologic cancer	2.14e-06	2.04e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTT1—hematologic cancer	2.14e-06	2.04e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—hematologic cancer	2.14e-06	2.04e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK14—hematologic cancer	2.12e-06	2.02e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AGRN—hematologic cancer	2.11e-06	2.01e-05	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	2.11e-06	2.01e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PIK3CA—hematologic cancer	2.1e-06	2.01e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SDC1—hematologic cancer	2.09e-06	1.99e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—hematologic cancer	2.09e-06	1.99e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—JUN—hematologic cancer	2.08e-06	1.99e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ESR1—hematologic cancer	2.08e-06	1.98e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	2.08e-06	1.98e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STAT3—hematologic cancer	2.07e-06	1.97e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRAS—hematologic cancer	2.06e-06	1.97e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—hematologic cancer	2.06e-06	1.97e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FN1—hematologic cancer	2.05e-06	1.96e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—hematologic cancer	2.04e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—BAD—hematologic cancer	2.03e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NFKBIA—hematologic cancer	2.03e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NQO1—hematologic cancer	2.03e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CD44—hematologic cancer	2.03e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1B—hematologic cancer	2.02e-06	1.93e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1A—hematologic cancer	2.02e-06	1.92e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTEN—hematologic cancer	2.01e-06	1.92e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOTCH1—hematologic cancer	2.01e-06	1.92e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—hematologic cancer	2e-06	1.91e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2e-06	1.91e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—IDH2—hematologic cancer	2e-06	1.91e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HMMR—hematologic cancer	2e-06	1.91e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—hematologic cancer	1.99e-06	1.9e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.99e-06	1.9e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAPK3—hematologic cancer	1.98e-06	1.89e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MAPK8—hematologic cancer	1.97e-06	1.88e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CD80—hematologic cancer	1.97e-06	1.88e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KIT—hematologic cancer	1.96e-06	1.87e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CG—hematologic cancer	1.96e-06	1.87e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTP1—hematologic cancer	1.96e-06	1.87e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—hematologic cancer	1.95e-06	1.86e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTPN11—hematologic cancer	1.93e-06	1.84e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—hematologic cancer	1.92e-06	1.83e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYCS—hematologic cancer	1.92e-06	1.83e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EP300—hematologic cancer	1.92e-06	1.83e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFB1—hematologic cancer	1.92e-06	1.83e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—hematologic cancer	1.91e-06	1.82e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HSP90AA1—hematologic cancer	1.91e-06	1.82e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—hematologic cancer	1.9e-06	1.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.88e-06	1.79e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	1.87e-06	1.79e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CREB1—hematologic cancer	1.87e-06	1.78e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—SRC—hematologic cancer	1.87e-06	1.78e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—hematologic cancer	1.86e-06	1.78e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1A—hematologic cancer	1.86e-06	1.78e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ABCB1—hematologic cancer	1.86e-06	1.77e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTEN—hematologic cancer	1.86e-06	1.77e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CG—hematologic cancer	1.85e-06	1.77e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—BRAF—hematologic cancer	1.85e-06	1.76e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL2—hematologic cancer	1.83e-06	1.75e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CA9—hematologic cancer	1.83e-06	1.74e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ACP5—hematologic cancer	1.83e-06	1.74e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6R—hematologic cancer	1.82e-06	1.74e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CREBBP—hematologic cancer	1.82e-06	1.74e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTM1—hematologic cancer	1.81e-06	1.72e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NCOR1—hematologic cancer	1.81e-06	1.72e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.8e-06	1.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—hematologic cancer	1.8e-06	1.72e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—EP300—hematologic cancer	1.8e-06	1.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRAS—hematologic cancer	1.8e-06	1.71e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NQO1—hematologic cancer	1.78e-06	1.7e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CD44—hematologic cancer	1.78e-06	1.7e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—hematologic cancer	1.78e-06	1.69e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EP300—hematologic cancer	1.77e-06	1.69e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SRC—hematologic cancer	1.75e-06	1.67e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAP2K1—hematologic cancer	1.74e-06	1.66e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CD—hematologic cancer	1.73e-06	1.65e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SRC—hematologic cancer	1.72e-06	1.64e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CREBBP—hematologic cancer	1.72e-06	1.64e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—hematologic cancer	1.72e-06	1.64e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MAPK3—hematologic cancer	1.72e-06	1.64e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—IDH1—hematologic cancer	1.72e-06	1.64e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.72e-06	1.64e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—hematologic cancer	1.7e-06	1.63e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.7e-06	1.62e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TXN—hematologic cancer	1.7e-06	1.62e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.7e-06	1.62e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTP1—hematologic cancer	1.69e-06	1.61e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NRAS—hematologic cancer	1.68e-06	1.61e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYCS—hematologic cancer	1.68e-06	1.6e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HSP90AA1—hematologic cancer	1.67e-06	1.59e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.66e-06	1.59e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—hematologic cancer	1.66e-06	1.59e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRAS—hematologic cancer	1.66e-06	1.58e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGF2—hematologic cancer	1.65e-06	1.58e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.64e-06	1.56e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CA—hematologic cancer	1.63e-06	1.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3R1—hematologic cancer	1.63e-06	1.56e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CD—hematologic cancer	1.63e-06	1.56e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—MAPK3—hematologic cancer	1.61e-06	1.54e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ALB—hematologic cancer	1.61e-06	1.54e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ABCB1—hematologic cancer	1.6e-06	1.53e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.6e-06	1.52e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—MTHFR—hematologic cancer	1.6e-06	1.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MAPK3—hematologic cancer	1.59e-06	1.51e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—JAK2—hematologic cancer	1.59e-06	1.51e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—hematologic cancer	1.58e-06	1.51e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TGFB1—hematologic cancer	1.56e-06	1.49e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTM1—hematologic cancer	1.55e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NCOR1—hematologic cancer	1.55e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.55e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.55e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MDM2—hematologic cancer	1.55e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—hematologic cancer	1.54e-06	1.47e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—hematologic cancer	1.54e-06	1.47e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFB1—hematologic cancer	1.54e-06	1.47e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3R1—hematologic cancer	1.54e-06	1.47e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.51e-06	1.45e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—hematologic cancer	1.51e-06	1.44e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CB—hematologic cancer	1.51e-06	1.44e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTP1—hematologic cancer	1.48e-06	1.41e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NUP98—hematologic cancer	1.47e-06	1.4e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—hematologic cancer	1.45e-06	1.38e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—hematologic cancer	1.44e-06	1.38e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—hematologic cancer	1.43e-06	1.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.42e-06	1.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.42e-06	1.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CB—hematologic cancer	1.42e-06	1.36e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CA—hematologic cancer	1.42e-06	1.35e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NUP214—hematologic cancer	1.41e-06	1.35e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1B—hematologic cancer	1.41e-06	1.35e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTR—hematologic cancer	1.39e-06	1.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.39e-06	1.32e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP3—hematologic cancer	1.38e-06	1.32e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—hematologic cancer	1.38e-06	1.32e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—MTHFR—hematologic cancer	1.37e-06	1.31e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTM1—hematologic cancer	1.36e-06	1.3e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NCOR1—hematologic cancer	1.36e-06	1.3e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ENO2—hematologic cancer	1.36e-06	1.3e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—hematologic cancer	1.35e-06	1.29e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—JUN—hematologic cancer	1.34e-06	1.28e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CG—hematologic cancer	1.34e-06	1.28e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—hematologic cancer	1.33e-06	1.27e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CA—hematologic cancer	1.33e-06	1.27e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.32e-06	1.26e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—hematologic cancer	1.31e-06	1.25e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CA—hematologic cancer	1.31e-06	1.25e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1A—hematologic cancer	1.3e-06	1.24e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTEN—hematologic cancer	1.3e-06	1.24e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SDC1—hematologic cancer	1.29e-06	1.23e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—hematologic cancer	1.29e-06	1.23e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK8—hematologic cancer	1.27e-06	1.21e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—hematologic cancer	1.26e-06	1.2e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CREBBP—hematologic cancer	1.24e-06	1.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EP300—hematologic cancer	1.24e-06	1.18e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—hematologic cancer	1.23e-06	1.17e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTEN—hematologic cancer	1.23e-06	1.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—hematologic cancer	1.21e-06	1.16e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.21e-06	1.16e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SRC—hematologic cancer	1.21e-06	1.15e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MTHFR—hematologic cancer	1.2e-06	1.15e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CD—hematologic cancer	1.18e-06	1.12e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—hematologic cancer	1.17e-06	1.12e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—EP300—hematologic cancer	1.17e-06	1.12e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—hematologic cancer	1.16e-06	1.11e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALB—hematologic cancer	1.16e-06	1.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRAS—hematologic cancer	1.16e-06	1.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—hematologic cancer	1.16e-06	1.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—hematologic cancer	1.16e-06	1.11e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CG—hematologic cancer	1.15e-06	1.1e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.11e-06	1.06e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK3—hematologic cancer	1.11e-06	1.06e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NQO1—hematologic cancer	1.1e-06	1.04e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CD44—hematologic cancer	1.1e-06	1.04e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—hematologic cancer	1.09e-06	1.04e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—hematologic cancer	1.08e-06	1.03e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFB1—hematologic cancer	1.08e-06	1.03e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—hematologic cancer	1.07e-06	1.02e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CREBBP—hematologic cancer	1.07e-06	1.02e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYCS—hematologic cancer	1.04e-06	9.89e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.03e-06	9.83e-06	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.03e-06	9.8e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CD—hematologic cancer	1.01e-06	9.69e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.01e-06	9.65e-06	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—hematologic cancer	9.99e-07	9.53e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3R1—hematologic cancer	9.58e-07	9.15e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CREBBP—hematologic cancer	9.38e-07	8.95e-06	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CA—hematologic cancer	9.18e-07	8.76e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTP1—hematologic cancer	9.13e-07	8.72e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CD—hematologic cancer	8.89e-07	8.49e-06	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—hematologic cancer	8.88e-07	8.47e-06	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTEN—hematologic cancer	8.88e-07	8.47e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CB—hematologic cancer	8.85e-07	8.44e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALB—hematologic cancer	8.78e-07	8.38e-06	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CA—hematologic cancer	8.66e-07	8.27e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCB1—hematologic cancer	8.65e-07	8.25e-06	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—hematologic cancer	8.49e-07	8.1e-06	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—EP300—hematologic cancer	8.46e-07	8.08e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3R1—hematologic cancer	8.4e-07	8.01e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NCOR1—hematologic cancer	8.39e-07	8.01e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTM1—hematologic cancer	8.39e-07	8.01e-06	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—hematologic cancer	8.13e-07	7.75e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CB—hematologic cancer	7.75e-07	7.4e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTEN—hematologic cancer	7.64e-07	7.29e-06	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—hematologic cancer	7.5e-07	7.15e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTHFR—hematologic cancer	7.42e-07	7.08e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—EP300—hematologic cancer	7.29e-07	6.96e-06	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—hematologic cancer	7.08e-07	6.75e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTEN—hematologic cancer	6.7e-07	6.39e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—EP300—hematologic cancer	6.39e-07	6.1e-06	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CA—hematologic cancer	6.26e-07	5.98e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CG—hematologic cancer	6.23e-07	5.95e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CREBBP—hematologic cancer	5.78e-07	5.51e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.48e-07	5.23e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALB—hematologic cancer	5.41e-07	5.16e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CA—hematologic cancer	5.39e-07	5.15e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3R1—hematologic cancer	5.17e-07	4.94e-06	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—hematologic cancer	5.12e-07	4.88e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CB—hematologic cancer	4.78e-07	4.56e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CA—hematologic cancer	4.72e-07	4.51e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—hematologic cancer	4.41e-07	4.2e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTEN—hematologic cancer	4.13e-07	3.94e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—EP300—hematologic cancer	3.94e-07	3.76e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—hematologic cancer	3.86e-07	3.68e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.91e-07	2.78e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—hematologic cancer	2.38e-07	2.27e-06	CbGpPWpGaD
